ANEB (Anebulo Pharmaceuticals) ROCE %: -89.72% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANEB Anebulo Pharmaceuticals Inc ANEB
35 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals ROCE %?

Anebulo Pharmaceuticals ANEB 35 ROCE % is -89.72% as of Dec. 2025. GuruFocus rates ANEB with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anebulo Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was -89.72%.

Anebulo Pharmaceuticals  (OTCPK:ANEB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anebulo Pharmaceuticals ROCE % Related Terms

Anebulo Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals ROCE % Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -249.77 -37.45 -91.42 -111.70 -104.76

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.01 -40.28 -67.74 -80.06 -89.72
ANEB
35GF Score
Anebulo Pharmaceuticals Inc ANEB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals ROCE % Calculation

Anebulo Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-8.103/( ( (4.073 - 0.261) + (12.146 - 0.488) )/ 2 )
=-8.103/( (3.812+11.658)/ 2 )
=-8.103/7.735
=-104.76 %

Anebulo Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-7.928/( ( (10.701 - 0.964) + (9.422 - 1.486) )/ 2 )
=-7.928/( ( 9.737 + 7.936 )/ 2 )
=-7.928/8.8365
=-89.72 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -89.72% mean?
Anebulo Pharmaceuticals (ANEB) has a ROCE % of -89.72% as of Dec. 2025.
Is Anebulo Pharmaceuticals' ROCE % too high?
Anebulo Pharmaceuticals' current ROCE % is -89.72%. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' ROCE % compare to PHIO and COCP?
Anebulo Pharmaceuticals' ROCE % of -89.72% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Anebulo Pharmaceuticals's current ROCE % is -89.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (ANEB) has a current ROCE % of -89.72%. The current ROCE % is -89.72%. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Anebulo Pharmaceuticals (ANEB), the current ROCE % is -89.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for ANEB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price